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The main research questions of  the study are: 
 
1. How does the institutional environment affect formation of networks between 
innovating institutions? 
2. How does the patent regime affect the formation of innovation networks? 
3. Is there an effect of patent regime in adoption of open innovation strategies? 
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 The primary method of data collection is 
interviewing; this is supplemented by 
observations and elements of ethnography. 
 
 The main method of analyzing the primary 
data is a variant of qualitative content 
analysis.  
 
 Secondary data sources are used to  
corroborate the primary research findings 
through: 1. Citation Analysis  2. Patent 
Analysis   3. Pipeline Analysis  4. 
Collaboration and  Alliances Data. 
 
12 semi structured interviews were conducted with employees from incumbent 
pharmaceutical firms, universities and public research labs and government 
departments. Selection of pilot cases was based on convenience, access and 
geographic proximity. Qualitative analysis of interview transcripts revealed 
several emergent themes which need to be probed further:  
Unit of  analysis: firms, universities and public research labs involved in 
research of New drugs (small molecules).  
 
Preliminary findings reveal low intensity of collaboration between  
firms-universities-public research labs 
 
 
 
 
 
 
 
 
 
 
³+RZmany IITs are there at Delhi, Bombay, Madras, Kharagpur these are the high profile 
ones. Have they formed a network amongst themselves for drug discovery so far"´± R&D 
Director, Company A 
 
³+LVWRULFDOO\we love working in isolation we work in silence. If you look at Indian classical 
music. Do you see any orchestra? but look at the western classical, everybody has to play in 
unison so that you build up VRPHWKLQJ´± R&D Director, Company B 
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The study aspires to have a national context to understand the nuances affecting 
the formation of the innovation networks in the light of the theory of national 
innovation system (NIS) (Christopher Freeman, 1992; Lundvall, 1992; David C 
Mowery,1992; Nelson Richard, 1993).  
The national environment in India for the pharmaceutical sector recently underwent 
changes with The Patents (Amendment) Act 2005, to comply with the TRIPS 
agreement leading to product patent protection. This has led to Government 
initiatives to support R&D and promote interlinkages between industry and 
academia. Globally, innovation ecosystem in recent years has morphed and seen 
a paradigm shift from a closed innovation in-house R&D model to more open 
approaches. In this context, the study aspires to gain an understanding of how the  
institutional and regulatory factors influence adoption of open innovation strategies 
at firm level and enables formation of innovation networks between universities, 
public research labs and firms in India.  
The major underpinning of the open innovation concept is that the in-house R&D 
structure is slowly getting replaced by network-based R&D firms specifically those 
engaged in new drug research. It would be interesting to know whether  open or 
closed  approach is predominant in Indian pharmaceutical firms undertaking 
innovation and  how the institutional  and regulatory environment affects such 
strategic  decisions.  
Source: Gassmann, Oliver, & Enkel, Ellen. (2004)  
